Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management

Houssein Safa, Fawzi Abu Rous, Neel Belani, Hossein Borghaei, Shirish Gadgeel, Balazs Halmos

Research output: Contribution to journalReview articlepeer-review

Abstract

Over the last decade, the use of targeted therapies and immune therapies led to drastic changes in the management lung cancer and translated to improved survival outcomes. This growing arsenal of therapies available for the management of non-small cell lung cancer added more complexity to treatment decisions. The genomic profiling of tumors and the molecular characterization of the tumor microenvironment gradually became essential steps in exploring and identifying markers that can enhance patient selection to facilitate treatment personalization and narrow down therapy options. The advent of innovative diagnostic platforms, such as next-generation sequencing and plasma genotyping (also known as liquid biopsies), has aided in this quest. Currently, programmed cell death ligand 1 expression remains the most recognized and fully validated predictive biomarker of response to immune checkpoint inhibitors. Other markers such as tumor mutational burden, tumor infiltrating lymphocytes, driver mutations, and other molecular elements of the tumor microenvironment bear the potential to be predictive tools; however, the majority are still investigational. In this review, we describe the advances noted thus far on currently validated as well as novel emerging biomarkers that have the potential to guide the use of immunotherapy agents in the management of non-small cell lung cancer.

Original languageEnglish (US)
JournalTargeted Oncology
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management'. Together they form a unique fingerprint.

Cite this